These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 10622038)

  • 1. Review of NNRTIs: 'today and tomorrow'.
    Katlama C
    Int J Clin Pract Suppl; 1999 Jun; 103():16-20. PubMed ID: 10622038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team.
    Staszewski S; Morales-Ramirez J; Tashima KT; Rachlis A; Skiest D; Stanford J; Stryker R; Johnson P; Labriola DF; Farina D; Manion DJ; Ruiz NM
    N Engl J Med; 1999 Dec; 341(25):1865-73. PubMed ID: 10601505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new approach to initial antiretroviral therapy: protease-sparing combination regimens.
    Hanna L
    BETA; 1998 Oct; ():9-13. PubMed ID: 11365999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new HAART on the horizon says the proof is in the potency.
    AIDS Alert; 1999 Apr; 14(4):37-9. PubMed ID: 11366218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [HIV infection: DuPont Pharma presents the results of its antiretroviral agent].
    Allerg Immunol (Paris); 1998 Apr; 30(4):123-4. PubMed ID: 9631694
    [No Abstract]   [Full Text] [Related]  

  • 6. Efavirenz in HIV infection.
    Casado JL; Moreno S
    N Engl J Med; 2000 Apr; 342(17):1290-1. PubMed ID: 10787332
    [No Abstract]   [Full Text] [Related]  

  • 7. New study shows efavirenz effective with d4T and 3TC.
    AIDS Alert; 1999 May; 14(5):60. PubMed ID: 11366404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of long-term efavirenz plus nucleoside reverse transcriptase inhibitors for HIV-1 infection.
    Tashima K; Staszewski S; Nelson M; Rachlis A; Skiest D; Stryker R; Bessen L; Overfield S; Ruiz N; Wirtz V
    AIDS; 2008 Jan; 22(2):275-9. PubMed ID: 18097230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An open-label, randomized comparative pilot study of a single-class quadruple therapy regimen versus a 2-class triple therapy regimen for individuals initiating antiretroviral therapy.
    Moyle G; Higgs C; Teague A; Mandalia S; Nelson M; Johnson M; Fisher M; Gazzard B
    Antivir Ther; 2006; 11(1):73-8. PubMed ID: 16518962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.
    Hammer SM; Squires KE; Hughes MD; Grimes JM; Demeter LM; Currier JS; Eron JJ; Feinberg JE; Balfour HH; Deyton LR; Chodakewitz JA; Fischl MA
    N Engl J Med; 1997 Sep; 337(11):725-33. PubMed ID: 9287227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quadruple nucleoside therapy with zidovudine, lamivudine, abacavir and tenofovir in the treatment of HIV.
    Stürmer M; Staszewski S; Doerr HW
    Antivir Ther; 2007; 12(5):695-703. PubMed ID: 17713153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triple nucleoside reverse transcriptase inhibitor- vs. nonnucleoside reverse transcriptase inhibitor-containing regimens as first-line therapy: efficacy and durability in a prospective cohort of French HIV-infected patients.
    Cuzin L; Pugliese P; Bugnon F; Delpierre C; Cua E; Billaud E; Massip P; Raffi F; Dellamonica P
    HIV Med; 2005 Nov; 6(6):388-95. PubMed ID: 16268820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of nucleoside reverse transcriptase inhibitor pairs in efavirenz-based regimens for treatment-naïve adults with HIV infection in the United States.
    Brogan AJ; Talbird SE; Cohen C
    Value Health; 2011; 14(5):657-64. PubMed ID: 21839403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DMP 266 and indinavir combination.
    AIDS Patient Care STDS; 1997 Aug; 11(4):287-8. PubMed ID: 11361845
    [No Abstract]   [Full Text] [Related]  

  • 16. A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease.
    Fischl MA; Ribaudo HJ; Collier AC; Erice A; Giuliano M; Dehlinger M; Eron JJ; Saag MS; Hammer SM; Vella S; Morse GD; Feinberg JE; Demeter LM; Eshleman SH;
    J Infect Dis; 2003 Sep; 188(5):625-34. PubMed ID: 12934177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative biological and clinical outcomes after a switch from a virologically unsuccessful first protease inhibitor-containing antiretroviral combination to a 3-drug regimen containing efavirenz, nevirapine, or abacavir.
    Abgrall S; Yeni PG; Bouchaud O; Costagliola D;
    Clin Infect Dis; 2007 Jan; 44(1):120-7. PubMed ID: 17143827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efavirenz in the management of HIV infection.
    Gazzard BG
    Int J Clin Pract; 1999; 53(1):60-4. PubMed ID: 10344069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triple-nucleoside regimens versus efavirenz.
    De Luca A; Di Giambenedetto S
    N Engl J Med; 2004 Aug; 351(7):717-9; author reply 717-9. PubMed ID: 15306677
    [No Abstract]   [Full Text] [Related]  

  • 20. Coming therapies: abacavir.
    Staszewski S
    Int J Clin Pract Suppl; 1999 Jun; 103():35-8. PubMed ID: 10622042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.